文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

程序性死亡受体1抗体耐药机制研究进展

[Resistance mechanism of programmed death-1 antibody].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

免疫治疗已成为继手术、放疗、化疗及靶向治疗后的重要肿瘤治疗方式,PD-1抗体在黑色素瘤等肿瘤中带来持续病灶稳定甚至完全缓解。然而耐药现象日益增多,其机制尚不明确。探索耐药机制、研发新型联合治疗模式、规避或逆转耐药,有助于调整治疗策略并提高疗效。

要点

  • PD-1抗体已获批用于黑色素瘤等肿瘤,可带来持续病灶稳定甚至完全缓解。
  • PD-1抗体耐药现象日益增多,但耐药机制目前知之甚少。
  • 探索耐药机制并研发新型联合治疗模式,有望规避或逆转耐药。

核心结论

  • PD-1抗体疗效显著但耐药现象日益增多,探索耐药机制并研发新型联合治疗模式有助于指导治疗策略调整、提高疗效并带来持久生存获益。

研究设计与样本

  • 本文为综述,总结PD-1抗体耐药机制相关研究进展,未报告具体检索范围与样本量。

主要发现

  • PD-1抗体在黑色素瘤等不同类型肿瘤中获批应用,表现为持续的病灶稳定,甚至完全缓解。
  • PD-1抗体表现出良好疗效和应用前景的同时,也出现了越来越多的耐药现象。
  • 目前关于PD-1抗体耐药的形成机制知之甚少。

临床怎么用

  • 临床应关注PD-1抗体耐药现象,探索耐药机制以指导适时调整治疗策略。
  • 研究新型免疫治疗联合模式,以规避耐药发生、减少耐药不良影响甚至逆转耐药。

局限性

  • 本文为综述,未报告具体检索范围、纳入研究数量及原始数据。
  • PD-1抗体耐药的形成机制目前尚不明确,缺乏可用数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accompanied with more elaborate and deeper exploration, immunotherapy has been considered one of the most important therapeutic manners for tumor treatment besides conventional operative, chemotherapeutic, radiotherapeutic and targeted-therapeutic strategies. The application of programmed death-1 (PD-1) antibody has provided a new therapeutic option for patients and becomes a research focus of immunotherapy field. PD-1 antibody has been permitted to apply to the treatment of different types of cancers such as melanoma. PD-1 has been demonstrated to be highly effective, including the steady tumor growth control, even complete remission acquired. Although the PD-1 antibody displays great therapeutic effectiveness and application prospects, an increasingly number of drug resistant phenomena have also occurred. Little has been known about the mechanisms of PD-1 antibody resistance by now. However, exploring this mechanism, innovating new treatment mode of drug combination, avoiding the occurrence of drug resistance and decreasing the adverse influence of drug resistance, even reversing it, will be useful to guide the adjustment of treatment strategies, continuously improve the effects of immunotherapy, and give patients long-term survival benefit. 随着研究的不断深入,免疫治疗已经成为继手术治疗、放疗、化疗及靶向治疗之后,肿瘤治疗的又一重要方式。程序性细胞死亡受体1(PD-1)抗体为患者提供了新的治疗选择,并成为免疫治疗领域的研究重点。PD-1抗体获批应用于恶性黑色素瘤等不同类型肿瘤的治疗,为大量患者带来临床获益,表现为持续的病灶稳定,甚至完全缓解。然而,PD-1抗体表现出良好疗效和应用前景的同时,也出现了越来越多的耐药现象。尽管目前关于PD-1抗体耐药的形成机制知之甚少,但是不断探索PD-1抗体的耐药机制,研究新型免疫治疗模式,规避耐药现象的发生,减少耐药的不良影响,甚至逆转耐药,将有助于指导临床适时调整治疗策略,不断提高免疫治疗的疗效,给患者带来更持久的生存获益。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xin D, Wang F. [Resistance mechanism of programmed death-1 antibody]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30139024. doi:10.3760/cma.j.issn.0253-3766.2018.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。